Kezar Life Sciences (NASDAQ:KZR) announced Friday that the FDA has granted a formal Type C meeting for the first quarter of 2026, a move that could revive the clinical path for its lead asset, zetomipzomib, following months of regulatory uncertainty.
Sanuwave Health (NASDAQ:SNWV) reported preliminary fourth-quarter revenue that reached an all-time high, as the medical device maker effectively navigated a volatile reimbursement landscape that has left many of its competitors in the wound-care sector reeling.
Mesoblast (NASDAQ:MESO) reported a breakout quarter for its flagship cellular medicine, Ryoncil, with sales jumping 60% to reach $35.1 million for the period ended December 31, 2025.
AnaptysBio (NASDAQ:ANAB) moved to dismantle a key legal pillar of GSK’s (NYSE:GSK) defense in the Delaware Chancery Court on Thursday, filing a motion to dismiss claims that the biotech "repudiated" its lucrative royalty agreement for the blockbuster-intent cancer drug Jemperli.
Johnson & Johnson (NYSE:JNJ) became the latest pharmaceutical titan to bow to White House pressure, announcing a voluntary agreement to lower prescription drug costs in exchange for an exemption from the administration’s aggressive new import tariffs.
The US House approved a bill to extend healthcare subsidies, though its future in the Senate remains unclear.
CorMedix (NASDAQ:CRMD) reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, alongside initial fiscal 2026 guidance and program updates.
Menlo Park, California-based Personalis (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, reported unaudited preliminary financial and operational results for the fourth quarter and full year ended December 31, 2025.
Acrivon Therapeutics (NASDAQ:ACRV) unveiled promising interim data from its lead oncology program on Thursday, demonstrating that its biomarker-driven approach can achieve significant results in patients with hard-to-treat serous endometrial cancer.
The company’s lead candidate, ACR-368, a selective CHK1/2 inhibitor, showed a 67% confirmed objective response rate (cORR) in a subset of patients identified by Acrivon’s proprietary "OncoSignature" biomarker.
Viking Therapeutics (NASDAQ:VKTX) finished enrolling patients in a clinical trial designed to test how different dosing schedules of its experimental obesity drug can help people keep weight off, a key step in its bid to compete with established giants in the metabolic space.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported positive interim data from its ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI in patients with eosinophilic esophagitis.
Watertown, Massachusetts-based Acrivon Therapeutics (NASDAQ:ACRV) provided an interim clinical update across its precision oncology pipeline, highlighted by promising response rates for its lead candidate ACR-368 in an ongoing Phase 2b trial.
